Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.29 USD

1.29
653,771

+0.01 (0.78%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $1.28 -0.01 (-0.78%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Accuray's (ARAY) Q1 Loss in Line, Revenues Beat Estimates

by Zacks Equity Research

Accuray (ARAY) rides high on its product and service segments in Q1.

    Zacks Equity Research

    Why Is Accuray (ARAY) Up 9.9% Since the Last Earnings Report?

    by Zacks Equity Research

    Accuray (ARAY) reported earnings about 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Zacks Equity Research

      Accuray (ARAY) Grapples With Falling Margin and Product Mix

      by Zacks Equity Research

      Accuray Inc.'s (ARAY) low product margins and unfavorable product mix will continue to be a drag on the company's performance.

        Zacks Equity Research

        Accuray (ARAY) Q4 Loss Wider Than Expected, Revenues Beat

        by Zacks Equity Research

        Accuray's (ARAY) new TomoTherapy product platform, also known as Radixact, continues to contribute to the top line. Solid Fiscal 2018 guidance instills investor confidence.

          Zacks Equity Research

          Accuray's Radixact Now Used by Boise Summit Cancer Center

          by Zacks Equity Research

          Accuray's (ARAY) Radixact system leverages on its flagship TomoTherapy platform. The company's top-line growth is dependent on TomoTherapy system sales.

            Zacks Equity Research

            New Strong Sell Stocks for July 24th

            by Zacks Equity Research

            Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

              Zacks Equity Research

              Accuray's Q4 Preliminary Results Fail to Cheer Investors

              by Zacks Equity Research

              Accuray (ARAY) announced its preliminary results for for the fourth quarter and fiscal 2017. Following the announcement, the company's stock lost over 2% in the last trading session to close at $4.70.

                Zacks Equity Research

                Accuray's Medical Systems to be Acquired by Dubai Hospital

                by Zacks Equity Research

                Accuray Inc. (ARAY) recently announced that it has signed an agreement with the Neuro Spinal Hospital in Dubai, United Arab Emirates.

                  Zacks Equity Research

                  New Strong Sell Stocks for July 10th

                  by Zacks Equity Research

                  Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                    Zacks Equity Research

                    Why Is Accuray (ARAY) Down 9.8% Since the Last Earnings Report?

                    by Zacks Equity Research

                    Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      Zacks Equity Research

                      Weakness Seen in Accuray (ARAY) Estimates: Should You Stay Away?

                      by Zacks Equity Research

                      Accuray Incorporated (ARAY) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.

                        Zacks Equity Research

                        Accuray (ARAY) Incurs Loss in Q3, Revenues Miss Estimates

                        by Zacks Equity Research

                        Accuray Inc.(ARAY) reported a loss of 6 cents per share in the third quarter of fiscal 2017, comparing unfavorably with the Zacks Consensus Estimate of earnings of a penny.

                          Zacks Equity Research

                          Is Accuray (ARAY) a Great Growth Stock?

                          by Zacks Equity Research

                          Accuray (ARAY) looks like an exciting pick for investors as it is poised for strong future growth.

                            Zacks Equity Research

                            Accuray TomoTherapy System Starts Cancer Treatment in Africa

                            by Zacks Equity Research

                            Accuray Inc. (ARAY) recently announced that the Radiotherapy and Medical Oncology Center of Sidi Abdellah, Algeria has finally initiated cancer treatment with the company's flagship TomoTherapy system.

                              Zacks Equity Research

                              Accuray (ARAY) Incurs Wider Loss in Q2, Misses on Revenue

                              by Zacks Equity Research

                              Accuray Inc. (ARAY) reported a loss of 11 cents per share in the second quarter of fiscal 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents.

                                Zacks Equity Research

                                Why Earnings Season Could Be Great for Accuray (ARAY)

                                by Zacks Equity Research

                                Accuray (ARAY) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.

                                  Zacks Equity Research

                                  Accuray: Hong Kong Sanatorium to Buy 3 Radixact Systems

                                  by Zacks Equity Research

                                  Accuray Incorporated (ARAY) has signed an agreement with Hong Kong Sanatorium & Hospital per which the latter would purchase three Radixact Systems.

                                    Zacks Equity Research

                                    5 MedTech Stocks Poised to Trump Earnings in Q4

                                    by Zacks Equity Research

                                    MedTech's steady earnings trend reflects a strong product cycle and continuing innovation.

                                      Zacks Equity Research

                                      4 Hot MedTech Stocks for Q4 Earnings

                                      by Zacks Equity Research

                                      The primary factor that compels us to bet on MedTech, is its fundamental defensive nature.